METHODS: Natural language processing (NLP) techniques were harnessed to preprocess the occupational injury narratives obtained from the US Occupational Safety and Health Administration (OSHA) from January 2015 to June 2023. The methodology involved meticulous preprocessing of textual narratives to standardize text and eliminate noise, followed by the innovative integration of Term Frequency-Inverse Document Frequency (TF-IDF) and Global Vector (GloVe) word embeddings for effective text representation. The proposed predictive model adopts a novel Bidirectional Long Short-Term Memory (Bi-LSTM) architecture and is further refined through model optimization, including random search hyperparameters and in-depth feature importance analysis. The optimized Bi-LSTM model has been compared and validated against other machine learning classifiers which are naïve Bayes, support vector machine, random forest, decision trees, and K-nearest neighbor.
RESULTS: The proposed optimized Bi-LSTM models' superior predictability, boasted an accuracy of 0.95 for hospitalization and 0.98 for amputation cases with faster model processing times. Interestingly, the feature importance analysis revealed predictive keywords related to the causal factors of occupational injuries thereby providing valuable insights to enhance model interpretability.
CONCLUSION: Our proposed optimized Bi-LSTM model offers safety and health practitioners an effective tool to empower workplace safety proactive measures, thereby contributing to business productivity and sustainability. This study lays the foundation for further exploration of predictive analytics in the occupational safety and health domain.
METHODS: Girls received 2 (months 0 and 6 [0, 6]: n = 301; months 0 and 12 [0, 12]: n = 151) or 3 doses (months 0,2, and 6 [0, 2, 6]: n = 301); boys received 2 doses ([0, 6]: n = 301; [0, 12]: n = 150); and young women received 3 doses ([0, 2, 6]: n = 314) of 9vHPV vaccine. Anti-HPV geometric mean titers (GMTs) were assessed by competitive Luminex immunoassay (cLIA) and immunoglobulin G-Luminex immunoassay (IgG-LIA) through month 36.
RESULTS: Anti-HPV GMTs were highest 1 month after the last 9vHPV vaccine regimen dose, decreased sharply during the subsequent 12 months, and then decreased more slowly. GMTs 2 to 2.5 years after the last regimen dose in girls and boys given 2 doses were generally similar to or greater than GMTs in young women given 3 doses. Across HPV types, most boys and girls who received 2 doses (cLIA: 81%-100%; IgG-LIA: 91%-100%) and young women who received 3 doses (cLIA: 78%-98%; IgG-LIA: 91%-100%) remained seropositive 2 to 2.5 years after the last regimen dose.
CONCLUSIONS: Antibody responses persisted through 2 to 2.5 years after the last dose of a 2-dose 9vHPV vaccine regimen in girls and boys. In girls and boys, antibody responses generated by 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy through at least 2 years after the second dose.